Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 5/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 2/20 | 0.32 |
| ▸ | MMP9 | P14780 | 2/20 | 0.32 |
| ▸ | CA12 | O43570 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA9 | Q16790 | 2/20 | 0.32 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16995324 | 1.00 | CHRM2 (0.42) | CHRM2CHRM1CHRM4CHRM3MEN1 | |
| SCHEMBL8573060 | 0.96 | CHRM2 (0.46) | CHRM2CHRM1CHRM4CHRM3MEN1 | |
| SCHEMBL7926060 | 0.84 | CHRM2 (0.48) | CHRM2CHRM1CHRM4CHRM3MEN1 | |
| SCHEMBL7926056 | 0.84 | CHRM2 (0.48) | CHRM2CHRM1CHRM4CHRM3MEN1 | |
| SCHEMBL7920287 | 0.84 | CHRM2 (0.48) | CHRM2CHRM1CHRM4CHRM3MEN1 | |
| SCHEMBL16672047 | 0.81 | CHRM2 (0.47) | CHRM2CHRM1CHRM4CHRM3MEN1 | |
| SCHEMBL17838825 | 0.80 | THRB (0.39) | MEN1KMT2ATHRBMMP2MMP9 | |
| SCHEMBL20739473 | 0.80 | THRB (0.39) | MEN1KMT2ATHRBMMP2MMP9 | |
| SCHEMBL20243545 | 0.80 | THRB (0.39) | MEN1KMT2ATHRBMMP2MMP9 | |
| SCHEMBL28592040 | 0.80 | THRB (0.39) | MEN1KMT2ATHRBMMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11254659-B1 | Capsaicinoid prodrug compounds and their use in treating medical conditions | CENTREXION THERAPEUTICS CORPORATION (US) | 2022-02-22 | — | — | US | disclosed |
| CN-108840908-A | A kind of novel crystal forms of telavi and preparation method thereof | 刘凤娟 | 2018-11-20 | — | — | CN | disclosed |
| CN-103608332-A | Pyridine-2-amides useful as CB2 agonists | HOFFMANN LA ROCHE | 2014-02-26 | — | — | CN | disclosed |
| EP-2203562-B1 | PROCESS FOR THE PREPARATION OF AN ENANTIOMERICALLY AND/OR DIASTEREOMERICALLY ENRICHED ESTER, THIOESTER, ALCOHOL OR THIOL | DSM IP ASSETS BV (NL) | 2012-04-18 | — | — | EP | disclosed |
| US-20100304451-A1 | PROCESS FOR THE PREPARATION OF AN ENANTIOMERICALLY AND/OR DIASTEREOMERICALLY ENRICHED ESTER, THIOESTER, ALCOHOL OR THIOL | DSM IP ASSETS B.V. (NL) | 2010-12-02 | — | — | US | disclosed |
| EP-2203562-A1 | PROCESS FOR THE PREPARATION OF AN ENANTIOMERICALLY AND/OR DIASTEREOMERICALLY ENRICHED ESTER, THIOESTER, ALCOHOL OR THIOL | DSM IP Assets B.V. (NL) | 2010-07-07 | — | — | EP | disclosed |
| WO-2009050216-A1 | PROCESS FOR THE PREPARATION OF AN ENANTIOMERICALLY AND/OR DIASTEREOMERICALLY ENRICHED ESTER, THIOESTER, ALCOHOL OR THIOL | DSM IP ASSETS BV (NL) | 2009-04-23 | — | — | WO | disclosed |
| EP-1432691-A1 | IMIDAZOLE-4-CARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF FOR TREATMENT OF OBESITY | Bayer Pharmaceuticals Corporation (US) | 2004-06-30 | — | — | EP | disclosed |
| WO-2003040107-A1 | IMIDAZOLE-4-CARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF FOR TREATMENT OF OBESITY | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254659-B1 | Capsaicinoid prodrug compounds and their use in treating medical conditions | TRPV1, TRPA1, TRPV2 | CHRM2 2999/4885CHRM1 3067/4885CHRM4 2762/4885 |
| US-20100304451-A1 | PROCESS FOR THE PREPARATION OF AN ENANTIOMERICALLY AND/OR DIASTEREOMERICALLY ENRICHED ESTER, THIOESTER, ALCOHOL OR THIOL | ADH1C, ACOT7, ADH5 | CHRM2 2972/4885CHRM1 2580/4885CHRM4 2889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.